Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
uniQure N.V. (QURE)
USD41.10
-1.53 (-3.59%)
NL NASDAQ Healthcare Biotechnology
Address
Paasheuvelweg 25 1105 BP
Amsterdam, NH, NL
Amsterdam, NH, NL
CEO
Matthew Kapusta
Website
uniqure.com
IPO
2014-02-05
CIK 1590560 ISIN NL0010696654
Also trades on
London Stock Exchange · 0EE0.L (USD)
NASDAQ Global Select · QURE (USD)
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD41.10
-1.53 (-3.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.00
Float Shares
57.62M
Free Float %
93.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.28% | +28.82% | +89.21% | +30.08% | -3.39% | +21.60% | +121.29% | +33.00% | -8.98% | +148.51% | +99.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (37 ratings, all time)
Buy
Price Targets & DCF
Current price
41.10
Low
10.00
-75.7%
Consensus
35.44
-13.8%
Median
35.00
-14.8%
High
60.00
+46.0%
Ratings Trend (MoM)
69% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
31.25
-24.0%
|
| Last Quarter | 10 |
31.10
-24.3%
|
| Last Year | 23 |
45.57
+10.9%
|
| All Time | 31 |
45.94
+11.8%
|
Quality scores
Altman Z-Score
-0.69
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-40.6% Q1'26: +127.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+29.7% Q1'26: -3.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,189.2% Q1'26: -1,077.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-815.9% Q1'26: -1,095.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-116.3% Q1'26: +41.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+18.2% Q1'26: +18.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.60× Q1'26: -0.44× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 8 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.30M
est: 8.74M (+17.9%)
|
25.10M
est: 18.28M (+37.3%)
|
13.11M
est: 12.60M (+4.0%)
|
11.28M
est: 12.78M (-11.7%)
|
7.28M
est: 6.22M (+17.0%)
|
37.51M
est: 116.44M (-67.8%)
|
524.00M
est: 475.82M (+10.1%)
|
106.48M
est: 30.57M (+248.3%)
|
15.84M
est: 27.71M (-42.8%)
|
27.12M
est: 39.44M (-31.2%)
|
16.10M
est: 15.78M (+2.0%)
|
20.76M
14.95M – 30.62M
+31.6% YoY
|
92.50M
45.15M – 206.85M
+345.5% YoY
|
174.87M
96.53M – 339.03M
+89.1% YoY
|
324.65M
179.21M – 629.44M
+85.7% YoY
|
482.32M
266.24M – 935.12M
+48.6% YoY
|
| EBITDA |
-72.48M
est: -5.93M (-1,122.5%)
|
-63.97M
est: -12.40M (-415.8%)
|
-69.74M
est: -8.54M (-716.1%)
|
-74.01M
est: -75.84M (+2.4%)
|
-113.72M
est: -4.22M (-2,593.6%)
|
-126.97M
est: -78.98M (-60.8%)
|
319.00M
est: 305.51M (+4.4%)
|
-108.02M
est: -133.73M (+19.2%)
|
-253.10M
est: -18.79M (-1,246.8%)
|
-160.75M
est: -26.75M (-500.9%)
|
-116.59M
est: -10.70M (-989.6%)
|
-14.08M
-20.77M – -10.14M
-31.6% YoY
|
-62.73M
-140.30M – -30.62M
-345.5% YoY
|
-118.60M
-229.95M – -65.47M
-89.1% YoY
|
-220.19M
-426.91M – -121.55M
-85.7% YoY
|
-327.13M
-634.24M – -180.57M
-48.6% YoY
|
| EBIT |
-80.69M
est: -5.95M (-1,255.5%)
|
-70.06M
est: -12.45M (-462.6%)
|
-77.23M
est: -8.58M (-800.1%)
|
-80.91M
est: -97.29M (+16.8%)
|
-120.39M
est: -4.24M (-2,739.9%)
|
-137.62M
est: -79.30M (-73.5%)
|
311.70M
est: 240.62M (+29.5%)
|
-116.56M
est: -216.82M (+46.2%)
|
-265.00M
est: -18.87M (-1,304.4%)
|
-173.39M
est: -26.86M (-545.5%)
|
-131.35M
est: -10.74M (-1,122.5%)
|
-14.14M
-20.85M – -10.18M
-31.6% YoY
|
-62.99M
-140.87M – -30.75M
-345.5% YoY
|
-119.09M
-230.89M – -65.74M
-89.1% YoY
|
-221.10M
-428.66M – -122.05M
-85.7% YoY
|
-328.47M
-636.85M – -181.32M
-48.6% YoY
|
| Net Income |
-78.15M
est: -162.25M (+51.8%)
|
-73.37M
est: -143.67M (+48.9%)
|
-80.39M
est: -144.10M (+44.2%)
|
-83.30M
est: -91.85M (+9.3%)
|
-124.20M
est: -135.37M (+8.3%)
|
-125.02M
est: -177.33M (+29.5%)
|
329.59M
est: 278.41M (+18.4%)
|
-126.79M
est: -186.75M (+32.1%)
|
-308.48M
est: -284.69M (-8.4%)
|
-239.56M
est: -199.00M (-20.4%)
|
-198.97M
est: -208.87M (+4.7%)
|
-218.21M
-241.22M – -180.92M
-4.5% YoY
|
-154.42M
-193.48M – -115.37M
+29.2% YoY
|
-114.65M
-194.11M – -35.19M
+25.8% YoY
|
-57.83M
-128.41M – -24.15M
+49.6% YoY
|
34.99M
14.61M – 77.70M
+160.5% YoY
|
| SGA |
21.12M
est: 14.40M (+46.7%)
|
26.00M
est: 30.12M (-13.7%)
|
25.04M
est: 20.76M (+20.6%)
|
25.31M
est: 21.05M (+20.2%)
|
33.54M
est: 10.26M (+227.1%)
|
42.58M
est: 191.84M (-77.8%)
|
56.29M
est: 87.13M (-35.4%)
|
54.70M
est: 50.37M (+8.6%)
|
73.08M
est: 61.85M (+18.2%)
|
50.68M
est: 88.04M (-42.4%)
|
65.34M
est: 35.22M (+85.5%)
|
46.34M
33.36M – 68.36M
+31.6% YoY
|
206.48M
100.78M – 461.76M
+345.5% YoY
|
390.35M
215.47M – 756.81M
+89.1% YoY
|
724.71M
400.04M – 1.41B
+85.7% YoY
|
1.08B
594.32M – 2.09B
+48.6% YoY
|
| EPS |
-3.54
est: -3.34 (-6.1%)
|
-2.93
est: -2.95 (+0.8%)
|
-2.98
est: -2.96 (-0.6%)
|
-2.34
est: -2.42 (+3.5%)
|
-3.20
est: -2.78 (-15.0%)
|
-2.81
est: -3.65 (+22.9%)
|
7.17
est: 6.17 (+16.2%)
|
-2.71
est: -3.75 (+27.7%)
|
-6.47
est: -5.91 (-9.4%)
|
-4.92
est: -4.08 (-20.5%)
|
-3.46
est: -3.87 (+10.7%)
|
-3.51
-4.19 – -3.15
+9.4% YoY
|
-3.05
-3.36 – -2.01
+13.2% YoY
|
-2.57
-3.38 – -0.61
+15.5% YoY
|
-1.01
-2.23 – -0.42
+60.9% YoY
|
0.61
0.25 – 1.35
+160.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-30 | Chardan Capital | Buy | Buy | Maintain |
| 2026-04-20 | Goldman Sachs | Neutral | Neutral | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-173.27M
OE per share TTM
-2.99
Owner's Yield
-9.49%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
54.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
33
Total invested
106.84M
Insider transactions (90d)
0
Beneficial owners (>5%)
41
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ryan Wilder | 3.93M | 8.20% | — | 3.93M | — | — | HC, IN | United States | 2024-02-13 | ↗ |
| 2 | Vestal Point Capital, LP | 3.93M | 8.20% | — | 3.93M | — | — | IA, PN | Delaware | 2024-02-13 | ↗ |
| 3 | Federated Hermes, Inc. | 3.86M | 8.67% | 3.86M | — | 3.86M | — | HC | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 4 | J. Christopher Donahue | 3.86M | 8.67% | — | 3.86M | — | 3.86M | IN | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 5 | Rhodora J. Donahue | 3.86M | 8.67% | — | 3.86M | — | 3.86M | IN | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 6 | Thomas R. Donahue | 3.86M | 8.67% | — | 3.86M | — | 3.86M | IN | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 7 | Voting Shares Irrevocable Trust | 3.86M | 8.67% | 3.86M | — | 3.86M | — | OO | Citizenship or place of Organization | 2021-02-12 | ↗ |
| 8 | Steven A. Cohen | 3.61M | 4.00% | — | 3.61M | — | 3.61M | IN | Citizenship or place of organization United States | 2022-02-11 | ↗ |
| 9 | Point72 Asset Management, L.P. | 3.61M | 4.00% | — | 3.61M | — | 3.61M | PN | Citizenship or place of organization Delaware | 2022-02-11 | ↗ |
| 10 | Point72 Capital Advisors, Inc. | 3.61M | 4.00% | — | 3.61M | — | 3.61M | CO | Citizenship or place of organization Delaware | 2022-02-11 | ↗ |
| 11 | . | 2.84M | 6.30% | — | — | — | 2.84M | PN | Channel Islands | 2021-04-30 | ↗ |
| 12 | Investment Management Limited | 2.84M | 6.30% | — | — | — | 2.84M | CO | Channel Islands | 2021-04-30 | ↗ |
| 13 | STATE STREET CORPORATION | 2.72M | 5.81% | — | 2.67M | — | 2.72M | HC | BOSTON, MASSACHUSETTS | 2023-02-03 | ↗ |
| 14 | Jeremy C. Green | 2.55M | 5.90% | — | 2.55M | — | 2.55M | HC, IN | — | 2020-02-14 | ↗ |
| 15 | Redmile Group, LLC | 2.55M | 5.90% | — | 2.55M | — | 2.55M | IA, OO | — | 2020-02-14 | ↗ |
| 16 | NAMES OF REPORTING PERSONS | 2.50M | 5.10% | — | 2.50M | — | 2.50M | OO | Delaware | 2024-07-18 | ↗ |
| 17 | SSGA FUNDS MANAGEMENT, INC. | 2.47M | 5.28% | — | 2.47M | — | 2.47M | IA | BOSTON, MASSACHUSETTS | 2023-02-03 | ↗ |
| 18 | Daniel Mack | 2.38M | 7.70% | — | 2.38M | — | — | HC | MA | 2018-02-14 | ↗ |
| 19 | Nantahala Capital Management, LLC | 2.38M | 7.70% | — | 2.38M | — | — | IA | MA | 2018-02-14 | ↗ |
| 20 | Wilmot B. Harkey | 2.38M | 7.70% | — | 2.38M | — | — | HC | MA | 2018-02-14 | ↗ |
| 21 | 98-0557567 | 2.37M | 5.10% | 2.22M | — | 2.37M | — | IA, HC | Bermuda | 2022-02-10 | ↗ |
| 22 | Consonance Capman GP LLC | 1.90M | 5.09% | — | 1.90M | — | — | HC, OO | Delaware USA | 2019-02-14 | ↗ |
| 23 | Mitchell Blutt | 1.90M | 5.09% | — | 1.90M | — | — | HC, IN | USA | 2019-02-14 | ↗ |
| 24 | Page 2 of 6 Pages | 1.87M | 6.06% | — | 1.87M | — | 1.87M | OO | The Netherlands | 2018-02-14 | ↗ |
| 25 | Consonance Capital Management LP | 1.82M | 4.88% | — | 1.82M | — | — | IA, PN | Delaware USA | 2019-02-14 | ↗ |
| 26 | James Tananbaum (“Tananbaum”) | 1.69M | 5.50% | 1.69M | 1.69M | 1.69M | — | IN | Delaware | 2017-11-03 | ↗ |
| 27 | Foresite Capital Fund IV, L.P. (“FCF IV”) | 1.59M | 5.10% | 1.59M | 1.59M | 1.59M | — | PN | Delaware | 2017-11-03 | ↗ |
| 28 | Foresite Capital Management IV, LLC (“FCM IV”) | 1.59M | 5.10% | 1.59M | 1.59M | 1.59M | — | OO | Delaware | 2017-11-03 | ↗ |
| 29 | Joseph Edelman | 1.27M | 5.03% | — | 1.27M | — | — | IN | Delaware, United States of America | 2017-02-14 | ↗ |
| 30 | Sciences Master Fund, Ltd. | 1.20M | 4.77% | — | 1.20M | — | — | CO | Delaware, United States of America | 2017-02-14 | ↗ |
| 31 | 2 | 1.05M | 3.40% | — | 1.05M | — | 1.05M | IA | Delaware | 2018-02-14 | ↗ |
| 32 | B.V. | 546.2K | 1.29% | — | 546.2K | — | 546.2K | OO | — | 2022-02-11 | ↗ |
| 33 | Management B.V. | 546.2K | 1.29% | — | 546.2K | — | 546.2K | OO | — | 2022-02-11 | ↗ |
| 34 | Foresite Capital Fund II, L.P. (“FCF II”) | 109.4K | 0.40% | 109.4K | 109.4K | 109.4K | — | PN | Delaware | 2017-11-03 | ↗ |
| 35 | Foresite Capital Management II, LLC (“FCM II”) | 109.4K | 0.40% | 109.4K | 109.4K | 109.4K | — | OO | Delaware | 2017-11-03 | ↗ |
| 36 | Consonance Capital Opportunity Fund Management LP | 77.7K | 0.21% | — | 77.7K | — | — | IA, PN | Delaware USA | 2019-02-14 | ↗ |
| 37 | Cubist Systematic Strategies, LLC | 2.3K | 4.00% | — | 2.3K | — | 2.3K | OO | Citizenship or place of organization Delaware | 2022-02-11 | ↗ |
| 38 | Partner Asset Management, LLC | 6.00 | 5.10% | — | 2.39M | — | 2.39M | OO | Delaware | 2022-07-18 | ↗ |
| 39 | Coller International General Partner V, L.P | — | 0.00% | — | — | — | — | PN | Guernsey, Channel Islands | 2022-09-26 | ↗ |
| 40 | Coller International Partners V-A, L.P | — | 0.00% | — | — | — | — | PN | Guernsey, Channel Islands | 2022-09-26 | ↗ |
| 41 | Coller Investment Management Limited | — | 0.00% | — | — | — | — | CO | Guernsey, Channel Islands | 2022-09-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
33
-227 vs prev Q
New positions
12
Closed positions
209
Increased
17
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 258.2K +258.2K (+100.0%) | 6.18B +6.2B (+100.0%) | 0.44% +0.441 pp | 0.01% +0.009 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 6.24M +181.4K (+3.0%) | 149.35M -204.4M (-57.8%) | 10.67% +0.310 pp | 0.01% -0.011 pp | USD48.69 -50.9% | 48 qtrs — |
| 3 | AVORO CAPITAL ADVISORS LLC | 6.15M +1.7M (+38.4%) | 147.17M -112.3M (-43.3%) | 10.51% +2.915 pp | 1.41% -1.938 pp | USD23.95 -0.1% | 5 qtrs — |
| 4 | RTW INVESTMENTS, LP | 3.71M -713.5K (-16.1%) | 88.82M -169.5M (-65.6%) | 6.34% -1.219 pp | 0.89% -2.293 pp | USD12.39 +93.1% | 6 qtrs — |
| 5 | ABRDN PLC | 3.68M +738.9K (+25.1%) | 88.03M -83.6M (-48.7%) | 6.29% +1.263 pp | 0.14% -0.135 pp | USD14.05 +70.3% | 9 qtrs — |
| 6 | STATE STREET CORP | 3.23M +1.8M (+123.8%) | 77.32M -7.0M (-8.3%) | 5.52% +3.054 pp | 0.00% 0.000 pp | USD23.00 +4.0% | 31 qtrs — |
| 7 | JPMORGAN CHASE & CO | 2.93M +1.8M (+155.3%) | 70.23M +3.1M (+4.7%) | 5.02% +2.918 pp | 0.00% +0.000 pp | USD20.56 +16.4% | 41 qtrs — |
| 8 | BLACKROCK, INC. | 1.97M +528.9K (+36.6%) | 47.26M -37.1M (-44.0%) | 3.38% +0.904 pp | 0.00% -0.001 pp | USD13.12 +82.4% | 6 qtrs — |
| 9 | TWO SIGMA INVESTMENTS, LP | 1.45M +553.7K (+61.7%) | 34.73M -17.7M (-33.7%) | 2.48% +0.946 pp | 0.05% -0.029 pp | USD13.43 +78.2% | 14 qtrs — |
| 10 | BIOIMPACT CAPITAL LLC | 1.38M +1.4M (+100.0%) | 33.06M +33.1M (+100.0%) | 2.36% +2.361 pp | 3.78% +3.783 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 11 | JENNISON ASSOCIATES LLC | 1.37M +371.7K (+37.2%) | 32.81M -25.5M (-43.8%) | 2.34% +0.635 pp | 0.02% -0.014 pp | USD44.50 -46.2% | 3 qtrs — |
| 12 | SUVRETTA CAPITAL MANAGEMENT, LLC | 1.22M +1.2M (+100.0%) | 29.12M +29.1M (+100.0%) | 2.08% +2.079 pp | 0.60% +0.596 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 13 | GOLDMAN SACHS GROUP INC | 1.17M +505.4K (+76.3%) | 27.94M -10.7M (-27.7%) | 2.00% +0.864 pp | 0.00% -0.001 pp | USD29.78 -19.6% | 33 qtrs — |
| 14 | TWO SIGMA ADVISERS, LP | 1.11M +700.9K (+171.2%) | 26.57M +2.7M (+11.2%) | 1.90% +1.198 pp | 0.05% +0.004 pp | USD17.03 +40.5% | 9 qtrs — |
| 15 | VANGUARD GROUP INC | 1.05M -73.7K (-6.6%) | 25.16M -40.5M (-61.7%) | 1.80% -0.126 pp | 0.00% -0.001 pp | USD30.08 -20.4% | 33 qtrs — |
| 16 | ARTIA GLOBAL PARTNERS LP | 1.02M +364.7K (+55.4%) | 24.49M -14.0M (-36.3%) | 1.75% +0.623 pp | 3.91% -2.182 pp | USD46.10 -48.1% | 2 qtrs — |
| 17 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 900.0K +300.0K (+50.0%) | 21.54M -13.5M (-38.5%) | 1.54% +0.513 pp | 1.07% -1.300 pp | USD16.53 +44.8% | 6 qtrs — |
| 18 | MILLENNIUM MANAGEMENT LLC | 803.6K +612.0K (+319.4%) | 19.23M +8.0M (+71.9%) | 1.37% +1.046 pp | 0.01% +0.003 pp | USD23.66 +1.1% | 48 qtrs — |
| 19 | AFFINITY ASSET ADVISORS, LLC | 800.0K +800.0K (+100.0%) | 19.14M +19.1M (+100.0%) | 1.37% +1.367 pp | 1.09% +1.091 pp | USD23.93 +0.0% | 3 qtrs — |
| 20 | GEODE CAPITAL MANAGEMENT, LLC | 776.1K +54.4K (+7.5%) | 18.58M -23.6M (-55.9%) | 1.33% +0.093 pp | 0.00% -0.002 pp | USD30.28 -21.0% | 37 qtrs — |
| 21 | FIERA CAPITAL CORP | 768.5K +768.5K (+100.0%) | 18.39M +18.4M (+100.0%) | 1.31% +1.313 pp | 0.06% +0.058 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 22 | FRANKLIN RESOURCES INC | 746.6K -1.2M (-62.5%) | 17.87M -98.2M (-84.6%) | 1.28% -2.122 pp | 0.00% -0.025 pp | USD17.78 +34.6% | 6 qtrs — |
| 23 | ORBIMED ADVISORS LLC | 737.4K +278.9K (+60.8%) | 17.65M -9.1M (-34.1%) | 1.26% +0.477 pp | 0.36% -0.269 pp | USD45.34 -47.2% | 2 qtrs — |
| 24 | MORGAN STANLEY | 716.9K +395.4K (+123.0%) | 17.16M -1.6M (-8.6%) | 1.23% +0.676 pp | 0.00% 0.000 pp | USD19.43 +23.2% | 48 qtrs — |
| 25 | NANTAHALA CAPITAL MANAGEMENT, LLC | 699.3K -308.2K (-30.6%) | 16.73M -42.1M (-71.5%) | 1.20% -0.527 pp | 0.55% -1.489 pp | USD20.41 +17.2% | 37 qtrs — |
| 26 | LOGOS GLOBAL MANAGEMENT LP | 675.0K +375.0K (+125.0%) | 16.15M -1.4M (-7.8%) | 1.15% +0.641 pp | 0.98% -0.594 pp | USD39.24 -39.0% | 2 qtrs — |
| 27 | TYRO CAPITAL MANAGEMENT LLC | 663.9K +663.9K (+100.0%) | 15.89M +15.9M (+100.0%) | 1.13% +1.135 pp | 2.84% +2.843 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 28 | MAVERICK CAPITAL LTD | 661.8K +661.8K (+100.0%) | 15.84M +15.8M (+100.0%) | 1.13% +1.131 pp | 0.17% +0.170 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 29 | CAPTION MANAGEMENT, LLC | 635.0K +254.0K (+66.7%) | 15.20M -7.0M (-31.7%) | 1.09% +0.434 pp | 0.10% -0.069 pp | USD18.09 +32.3% | 28 qtrs — |
| 30 | ASSENAGON ASSET MANAGEMENT S.A. | 606.9K +606.9K (+100.0%) | 14.52M +14.5M (+100.0%) | 1.04% +1.037 pp | 0.02% +0.020 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 31 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 521.7K +— (+0.0%) | 12.48M -18.0M (-59.0%) | 0.89% +0.000 pp | 1.11% -1.245 pp | USD58.37 -59.0% | 2 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 498.8K -385.2K (-43.6%) | 11.94M -39.7M (-76.9%) | 0.85% -0.658 pp | 0.00% -0.005 pp | USD29.63 -19.2% | 33 qtrs — |
| 33 | EVENTIDE ASSET MANAGEMENT, LLC | 498.2K +498.2K (+100.0%) | 11.92M +11.9M (+100.0%) | 0.85% +0.851 pp | 0.19% +0.186 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 34 | UBS GROUP AG | 491.5K +286.5K (+139.7%) | 11.76M -204.7K (-1.7%) | 0.84% +0.490 pp | 0.00% +0.000 pp | USD20.10 +19.1% | 44 qtrs — |
| 35 | CITADEL ADVISORS LLC | 483.2K -120.8K (-20.0%) | 11.56M -23.7M (-67.2%) | 0.83% -0.206 pp | 0.00% -0.004 pp | USD49.42 -51.6% | 33 qtrs — |
| 36 | WHITEFORT CAPITAL MANAGEMENT, LP | 459.0K +459.0K (+100.0%) | 10.98M +11.0M (+100.0%) | 0.78% +0.784 pp | 2.81% +2.808 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 37 | PRIVIUM FUND MANAGEMENT B.V. | 416.3K +30.3K (+7.8%) | 9.96M -12.6M (-55.8%) | 0.71% +0.052 pp | 1.83% -2.216 pp | USD12.03 +98.9% | 17 qtrs — |
| 38 | 683 CAPITAL MANAGEMENT, LLC | 385.0K -685.1K (-64.0%) | 9.21M -53.2M (-85.3%) | 0.66% -1.171 pp | 0.40% -2.862 pp | USD15.48 +54.6% | 37 qtrs — |
| 39 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 362.9K +5.2K (+1.5%) | 8.68M -12.2M (-58.4%) | 0.62% +0.009 pp | 0.00% -0.002 pp | USD30.47 -21.5% | 22 qtrs — |
| 40 | READYSTATE ASSET MANAGEMENT LP | 361.6K +361.6K (+100.0%) | 8.65M +8.7M (+100.0%) | 0.62% +0.618 pp | 0.35% +0.351 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 41 | JANE STREET GROUP, LLC | 354.4K -284.2K (-44.5%) | 8.48M -28.8M (-77.2%) | 0.61% -0.486 pp | 0.00% -0.004 pp | USD53.66 -55.4% | 6 qtrs — |
| 42 | FRED ALGER MANAGEMENT, LLC | 344.9K -945.5K (-73.3%) | 8.25M -67.1M (-89.0%) | 0.59% -1.616 pp | 0.03% -0.261 pp | USD58.37 -59.0% | 2 qtrs — |
| 43 | BANK OF AMERICA CORP /DE/ | 329.5K +34.4K (+11.7%) | 7.89M -9.3M (-54.2%) | 0.56% +0.025 pp | 0.00% -0.001 pp | USD34.58 -30.8% | 41 qtrs — |
| 44 | FIRST TURN MANAGEMENT, LLC | 321.7K +321.7K (+100.0%) | 7.70M +7.7M (+100.0%) | 0.55% +0.550 pp | 0.88% +0.880 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 45 | HRT FINANCIAL LP | 310.1K +310.1K (+100.0%) | 7.42M +7.4M (+100.0%) | 0.53% +0.530 pp | 0.02% +0.023 pp | USD23.93 +0.0% | 3 qtrs — |
| 46 | JUMP FINANCIAL, LLC | 306.1K +306.1K (+100.0%) | 7.33M +7.3M (+100.0%) | 0.52% +0.523 pp | 0.09% +0.090 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 47 | DIADEMA PARTNERS LP | 301.8K +1.8K (+0.6%) | 7.22M -10.3M (-58.8%) | 0.52% +0.003 pp | 1.24% -3.235 pp | USD58.16 -58.9% | 2 qtrs — |
| 48 | BOXER CAPITAL MANAGEMENT, LLC | 290.0K -510.0K (-63.8%) | 6.94M -39.8M (-85.1%) | 0.50% -0.964 pp | 1.52% -13.365 pp | USD17.04 +40.4% | 5 qtrs — |
| 49 | CATALIO CAPITAL MANAGEMENT, LP | 288.3K +5.4K (+1.9%) | 6.90M -9.6M (-58.2%) | 0.49% +0.009 pp | 1.22% -1.834 pp | USD17.78 +34.6% | 5 qtrs — |
| 50 | CENTIVA CAPITAL, LP | 268.3K +34.7K (+14.9%) | 6.42M -7.2M (-52.9%) | 0.46% +0.059 pp | 0.05% -0.078 pp | USD50.60 -52.7% | 3 qtrs — |
| 51 | PARKMAN HEALTHCARE PARTNERS LLC | 257.4K -88.0K (-25.5%) | 6.16M -14.0M (-69.4%) | 0.44% -0.150 pp | 0.59% -1.516 pp | USD15.65 +52.9% | 5 qtrs — |
| 52 | ADAR1 CAPITAL MANAGEMENT, LLC | 235.2K +101.8K (+76.4%) | 5.63M -2.2M (-27.7%) | 0.40% +0.174 pp | 0.41% -0.318 pp | USD43.46 -44.9% | 2 qtrs — |
| 53 | FRESHFORD CAPITAL MANAGEMENT, LLC | 229.6K +229.6K (+100.0%) | 5.49M +5.5M (+100.0%) | 0.39% +0.392 pp | 2.20% +2.204 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 54 | BNP PARIBAS ARBITRAGE, SNC | 221.3K -164.3K (-42.6%) | 5.30M -17.2M (-76.5%) | 0.38% -0.281 pp | 0.00% -0.010 pp | USD8.48 +182.2% | 23 qtrs — |
| 55 | VOSS CAPITAL, LLC | 210.0K +85.0K (+68.0%) | 5.03M -2.3M (-31.1%) | 0.36% +0.145 pp | 0.24% -0.112 pp | USD17.98 +33.1% | 3 qtrs — |
| 56 | PRICE T ROWE ASSOCIATES INC /MD/ | 208.6K -704.5K (-77.2%) | 4.99M -48.3M (-90.6%) | 0.36% -1.204 pp | 0.00% -0.005 pp | USD58.37 -59.0% | 2 qtrs — |
| 57 | EAGLE HEALTH INVESTMENTS LP | 205.2K +205.2K (+100.0%) | 4.91M +4.9M (+100.0%) | 0.35% +0.351 pp | 1.08% +1.079 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 58 | ALLY BRIDGE GROUP (NY) LLC | 200.0K +200.0K (+100.0%) | 4.79M +4.8M (+100.0%) | 0.34% +0.342 pp | 4.99% +4.986 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 59 | CITIGROUP INC | 184.8K +173.2K (+1,496.2%) | 4.42M +3.7M (+554.4%) | 0.32% +0.296 pp | 0.00% +0.002 pp | USD23.11 +3.5% | 29 qtrs — |
| 60 | PEAK6 LLC | 179.5K +168.4K (+1,517.1%) | 4.30M +3.6M (+563.0%) | 0.31% +0.288 pp | 0.01% +0.007 pp | USD23.28 +2.8% | 5 qtrs — |
| 61 | SOFINNOVA INVESTMENTS, INC. | 176.5K +39.7K (+29.0%) | 4.22M -3.8M (-47.1%) | 0.30% +0.068 pp | 0.18% -0.255 pp | USD15.28 +56.6% | 4 qtrs — |
| 62 | SQUAREPOINT OPS LLC | 176.0K -5.9K (-3.2%) | 4.21M -6.4M (-60.3%) | 0.30% -0.010 pp | 0.00% -0.006 pp | USD11.70 +104.5% | 6 qtrs — |
| 63 | NORTHERN TRUST CORP | 168.8K +16.4K (+10.7%) | 4.04M -4.9M (-54.6%) | 0.29% +0.028 pp | 0.00% -0.001 pp | USD30.40 -21.3% | 31 qtrs — |
| 64 | RAFFERTY ASSET MANAGEMENT, LLC | 164.9K +82.1K (+99.1%) | 3.95M -889.4K (-18.4%) | 0.28% +0.140 pp | 0.01% -0.002 pp | USD21.30 +12.3% | 4 qtrs — |
| 65 | BARCLAYS PLC | 162.5K -27.8K (-14.6%) | 3.89M -7.2M (-65.0%) | 0.28% -0.048 pp | 0.00% -0.002 pp | USD35.02 -31.7% | 3 qtrs — |
| 66 | ALYESKA INVESTMENT GROUP, L.P. | 151.1K +111.1K (+277.6%) | 3.61M +1.3M (+54.8%) | 0.26% +0.190 pp | 0.01% +0.003 pp | USD33.05 -27.6% | 2 qtrs — |
| 67 | NEW YORK STATE COMMON RETIREMENT FUND | 147.5K +147.5K (+100.0%) | 3.53M +3.5M (+100.0%) | 0.25% +0.252 pp | 0.00% +0.005 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 68 | — | 146.5K +146.5K (+100.0%) | 3.51M +3.5M (+100.0%) | 0.25% +0.250 pp | 2.61% +2.606 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 69 | BALYASNY ASSET MANAGEMENT L.P. | 135.6K -197.6K (-59.3%) | 3.25M -16.2M (-83.3%) | 0.23% -0.338 pp | 0.00% -0.021 pp | USD13.73 +74.3% | 12 qtrs — |
| 70 | D. E. SHAW & CO., INC. | 132.0K +99.4K (+305.6%) | 3.16M +1.3M (+66.3%) | 0.23% +0.170 pp | 0.00% +0.001 pp | USD23.15 +3.4% | 11 qtrs — |
| 71 | SILVERARC CAPITAL MANAGEMENT, LLC | 126.0K -329.0K (-72.3%) | 3.02M -23.5M (-88.6%) | 0.22% -0.562 pp | 0.42% -3.162 pp | USD38.65 -38.1% | 5 qtrs — |
| 72 | HUDSON BAY CAPITAL MANAGEMENT LP | 125.5K +121.2K (+2,806.4%) | 3.00M +2.8M (+1,091.6%) | 0.21% +0.207 pp | 0.01% +0.009 pp | USD23.56 +1.6% | 25 qtrs — |
| 73 | SCHONFELD STRATEGIC ADVISORS LLC | 122.5K -65.7K (-34.9%) | 2.93M -8.1M (-73.3%) | 0.21% -0.112 pp | 0.01% -0.049 pp | USD27.34 -12.5% | 12 qtrs — |
| 74 | NAN FUNG TRINITY (HK) LTD | 115.5K +115.5K (+100.0%) | 2.76M +2.8M (+100.0%) | 0.20% +0.197 pp | 0.22% +0.219 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 75 | SIMPLEX TRADING, LLC | 110.7K +42.7K (+62.8%) | 2.65M -1.3M (-33.3%) | 0.19% +0.073 pp | 0.00% -0.001 pp | USD18.00 +32.9% | 39 qtrs — |
| 76 | ENVESTNET ASSET MANAGEMENT INC | 99.6K +88.0K (+762.4%) | 2.38M +1.7M (+253.5%) | 0.17% +0.151 pp | 0.00% +0.001 pp | USD27.92 -14.3% | 2 qtrs — |
| 77 | IKARIAN CAPITAL, LLC | 91.1K +32.5K (+55.4%) | 2.18M -1.2M (-36.3%) | 0.16% +0.056 pp | 0.17% -0.175 pp | USD17.50 +36.7% | 3 qtrs — |
| 78 | JEFFERIES FINANCIAL GROUP INC. | 90.5K +— (+0.0%) | 2.17M -3.1M (-59.0%) | 0.15% +0.000 pp | 0.01% -0.014 pp | USD13.94 +71.7% | 3 qtrs — |
| 79 | MAREX GROUP PLC | 86.0K -866.0 (-1.0%) | 2.06M -3.0M (-59.4%) | 0.15% -0.002 pp | 0.01% -0.023 pp | USD58.37 -59.0% | 2 qtrs — |
| 80 | ROYAL BANK OF CANADA | 85.6K -125.8K (-59.5%) | 2.05M -10.3M (-83.4%) | 0.15% -0.215 pp | 0.00% -0.002 pp | USD14.67 +63.1% | 46 qtrs — |
| 81 | CLEARLINE CAPITAL LP | 83.7K +83.7K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.14% +0.143 pp | 0.10% +0.099 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 82 | CAPITAL FUND MANAGEMENT S.A. | 83.0K +83.0K (+100.0%) | 1.99M +2.0M (+100.0%) | 0.14% +0.142 pp | 0.01% +0.006 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 83 | UBS ASSET MANAGEMENT AMERICAS INC | 80.2K +80.2K (+100.0%) | 1.92M +1.9M (+100.0%) | 0.14% +0.137 pp | 0.00% +0.000 pp | USD23.93 +0.0% | 3 qtrs — |
| 84 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 79.4K +79.4K (+100.0%) | 1.90M +1.9M (+100.0%) | 0.14% +0.136 pp | 0.18% +0.178 pp | USD23.93 +0.0% | 1 qtrs NEW |
| 85 | SWISS NATIONAL BANK | 79.0K +2.7K (+3.5%) | 1.89M -2.6M (-57.6%) | 0.14% +0.005 pp | 0.00% -0.002 pp | USD14.28 +67.6% | 3 qtrs — |
| 86 | WALLEYE CAPITAL LLC | 79.0K -23.9K (-23.2%) | 1.89M -4.1M (-68.5%) | 0.14% -0.041 pp | 0.01% -0.017 pp | USD58.37 -59.0% | 16 qtrs — |
| 87 | ATOM INVESTORS LP | 78.2K +30.9K (+65.4%) | 1.87M -888.8K (-32.2%) | 0.13% +0.053 pp | 0.15% -0.061 pp | USD44.75 -46.5% | 2 qtrs — |
| 88 | MOORE CAPITAL MANAGEMENT, LP | 75.0K +75.0K (+100.0%) | 1.79M +1.8M (+100.0%) | 0.13% +0.128 pp | 0.03% +0.026 pp | USD23.93 +0.0% | 12 qtrs — |
| 89 | TUDOR INVESTMENT CORP ET AL | 74.0K +45.3K (+157.8%) | 1.77M +95.5K (+5.7%) | 0.13% +0.074 pp | 0.00% +0.000 pp | USD37.29 -35.8% | 2 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.63
Neutral
Ratio by volume
3.00
Bullish
Buys
10
Sells
16
Shares acquired
513.6K
Shares disposed
162.8K
Cash buys
—
Cash sales
14.00
Net activity
+350,794
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Potts Jeannette | Officer | A-Award | A | Stock Option (Right to Buy) | 57,200 | 9.04 | 517.1K | 57,200 | D | ↗ |
| 2026-03-04 | O'Keefe Kylie | Officer | A-Award | A | Ordinary Shares | 19,800 | 0.00 | — | 124,800 | D | ↗ |
| 2026-03-04 | Kapusta Matthew C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 113,800 | 9.04 | 1.03M | 113,800 | D | ↗ |
| 2026-03-04 | KLEMT CHRISTIAN | Officer | A-Award | A | Stock Option (Right to Buy) | 63,900 | 9.04 | 577.7K | 63,900 | D | ↗ |
| 2026-03-04 | Abi-Saab Walid | Officer | S-Sale | D | Ordinary Shares | 808 | 9.06 | 7.3K | 189,669 | D | ↗ |
| 2026-03-02 | Potts Jeannette | Officer | S-Sale | D | Ordinary Shares | 8,578 | 9.95 | 85.4K | 106,495 | D | ↗ |
| 2026-03-02 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 34,437 | 9.95 | 342.6K | 604,639 | D | ↗ |
| 2026-03-02 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 12,532 | 9.95 | 124.7K | 198,981 | D | ↗ |
| 2026-03-02 | Abi-Saab Walid | Officer | S-Sale | D | Ordinary Shares | 1,660 | 9.95 | 16.5K | 148,777 | D | ↗ |
| 2026-02-25 | O'Keefe Kylie | Officer | — | — | Stock Option (Right to Buy) | 180,000 | 16.22 | 2.92M | 0 | D | ↗ |
| 2026-02-25 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 12,378 | 23.86 | 295.3K | 639,076 | D | ↗ |
| 2026-02-25 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 6,217 | 23.86 | 148.3K | 211,513 | D | ↗ |
| 2026-01-12 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 7,803 | 25.09 | 195.8K | 32,342 | D | ↗ |
| 2026-01-09 | Kaye Jack | Director | M-Exempt | A | Ordinary Shares | 6,390 | 19.39 | 123.9K | 26,829 | D | ↗ |
| 2025-11-06 | Gut Robert | Director | M-Exempt | A | Ordinary Shares | 15,840 | 4.57 | 72.4K | 71,579 | D | ↗ |
| 2025-11-04 | Kaye Jack | Director | M-Exempt | A | Ordinary Shares | 10,000 | 7.37 | 73.7K | 30,439 | D | ↗ |
| 2025-09-26 | KLEMT CHRISTIAN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 5.37 | 80.6K | 0 | D | ↗ |
| 2025-09-24 | Kapusta Matthew C | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 175,000 | 6.22 | 1.09M | 0 | D | ↗ |
| 2025-09-24 | KLEMT CHRISTIAN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 13.03 | 39.1K | 0 | D | ↗ |
| 2025-06-27 | Abi-Saab Walid | Officer | S-Sale | D | Ordinary Shares | 1,466 | 13.92 | 20.4K | 150,437 | D | ↗ |
| 2025-06-20 | Springhorn Jeremy P. | Director | S-Sale | D | Ordinary Shares | 2,112 | 14.45 | 30.5K | 37,694 | D | ↗ |
| 2025-06-20 | POST LEONARD E | Director | S-Sale | D | Ordinary Shares | 2,112 | 14.45 | 30.5K | 29,937 | D | ↗ |
| 2025-06-20 | Meek David D. | Director | S-Sale | D | Ordinary Shares | 2,112 | 14.45 | 30.5K | 34,190 | D | ↗ |
| 2025-06-20 | Kaye Jack | Director | S-Sale | D | Ordinary Shares | 2,112 | 14.45 | 30.5K | 20,439 | D | ↗ |
| 2025-06-20 | Jacques Rachelle Suzanne | Director | S-Sale | D | Ordinary Shares | 2,112 | 14.45 | 30.5K | 28,346 | D | ↗ |
| 2025-06-20 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 3,336 | 14.45 | 48.2K | 56,879 | D | ↗ |
| 2025-06-20 | Balachandran Madhavan | Director | S-Sale | D | Ordinary Shares | 2,112 | 14.45 | 30.5K | 37,697 | D | ↗ |
| 2025-06-16 | Potts Jeannette | Officer | S-Sale | D | Ordinary Shares | 4,670 | 15.14 | 70.7K | 115,073 | D | ↗ |
| 2025-06-11 | Springhorn Jeremy P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 16.22 | 253.5K | 15,630 | D | ↗ |
| 2025-06-11 | POST LEONARD E | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 16.22 | 253.5K | 15,630 | D | ↗ |
| 2025-06-11 | Meek David D. | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 16.22 | 253.5K | 15,630 | D | ↗ |
| 2025-06-11 | Kaye Jack | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 16.22 | 253.5K | 15,630 | D | ↗ |
| 2025-06-11 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 16.22 | 253.5K | 15,630 | D | ↗ |
| 2025-06-11 | Gut Robert | Director | A-Award | A | Ordinary Shares | 7,970 | 0.00 | — | 60,215 | D | ↗ |
| 2025-06-11 | Balachandran Madhavan | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 16.22 | 253.5K | 15,630 | D | ↗ |
| 2025-03-04 | Potts Jeannette | Officer | S-Sale | D | Ordinary Shares | 7,076 | 10.29 | 72.8K | 119,743 | D | ↗ |
| 2025-03-04 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 28,341 | 10.29 | 291.6K | 651,454 | D | ↗ |
| 2025-03-04 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 10,438 | 10.29 | 107.4K | 217,730 | D | ↗ |
| 2025-03-04 | Abi-Saab Walid | Officer | S-Sale | D | Ordinary Shares | 1,350 | 10.29 | 13.9K | 151,903 | D | ↗ |
| 2025-03-03 | Potts Jeannette | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 10.90 | 654.0K | 60,000 | D | ↗ |
| 2025-03-03 | Kapusta Matthew C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 171,000 | 10.90 | 1.86M | 171,000 | D | ↗ |
| 2025-03-03 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 73,000 | 0.00 | — | 228,168 | D | ↗ |
| 2025-03-03 | Abi-Saab Walid | Officer | A-Award | A | Stock Option (Right to Buy) | 66,000 | 10.90 | 719.4K | 66,000 | D | ↗ |
| 2025-02-27 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 6,717 | 11.32 | 76.0K | 580,795 | D | ↗ |
| 2025-02-27 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 2,916 | 11.32 | 33.0K | 155,168 | D | ↗ |
| 2025-02-26 | Kapusta Matthew C | Director / Officer | A-Award | A | Ordinary Shares | 16,324 | 0.00 | — | 587,512 | D | ↗ |
| 2025-02-26 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 5,712 | 0.00 | — | 158,084 | D | ↗ |
| 2025-02-25 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 26,727 | 10.70 | 286.0K | 571,188 | D | ↗ |
| 2025-02-25 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 14,341 | 10.70 | 153.4K | 152,372 | D | ↗ |
| 2024-12-10 | Kapusta Matthew C | Director / Officer | M-Exempt | A | Ordinary Shares | 100,000 | 14.71 | 1.47M | 697,915 | D | ↗ |
| 2024-12-09 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 3,418 | 7.63 | 26.1K | 597,915 | D | ↗ |
| 2024-12-09 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 1,796 | 7.55 | 13.6K | 166,713 | D | ↗ |
| 2024-12-08 | Kapusta Matthew C | Director / Officer | A-Award | A | Ordinary Shares | 10,494 | 0.00 | — | 601,333 | D | ↗ |
| 2024-12-08 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 3,672 | 0.00 | — | 168,509 | D | ↗ |
| 2024-06-26 | Abi-Saab Walid | Officer | S-Sale | D | Ordinary Shares | 1,447 | 4.36 | 6.3K | 115,253 | — | ↗ |
| 2024-06-19 | Springhorn Jeremy P. | Director | A-Award | A | Stock Option (Right to Buy) | 15,840 | 4.57 | 72.4K | 15,840 | — | ↗ |
| 2024-06-19 | POST LEONARD E | Director | A-Award | A | Stock Option (Right to Buy) | 15,840 | 4.57 | 72.4K | 15,840 | — | ↗ |
| 2024-06-19 | Meek David D. | Director | A-Award | A | Stock Option (Right to Buy) | 15,840 | 4.57 | 72.4K | 15,840 | — | ↗ |
| 2024-06-19 | Kaye Jack | Director | A-Award | A | Ordinary Shares | 8,080 | 0.00 | — | 14,581 | — | ↗ |
| 2024-06-19 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option (Right to Buy) | 15,840 | 4.57 | 72.4K | 15,840 | — | ↗ |
| 2024-06-19 | Gut Robert | Director | A-Award | A | Stock Option (Right to Buy) | 15,840 | 4.57 | 72.4K | 15,840 | — | ↗ |
| 2024-06-19 | Balachandran Madhavan | Director | A-Award | A | Ordinary Shares | 8,080 | 0.00 | — | 31,839 | — | ↗ |
| 2024-06-17 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 1,611 | 4.80 | 7.7K | 164,837 | — | ↗ |
| 2024-06-17 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 2,936 | 4.81 | 14.1K | 115,707 | — | ↗ |
| 2024-06-13 | Springhorn Jeremy P. | Director | S-Sale | D | Ordinary Shares | 2,231 | 5.12 | 11.4K | 23,756 | — | ↗ |
| 2024-06-13 | Soteropoulos Paula | Director | S-Sale | D | Ordinary Shares | 2,220 | 5.14 | 11.4K | 20,203 | — | ↗ |
| 2024-06-13 | Potts Jeannette | Officer | S-Sale | D | Ordinary Shares | 4,781 | 4.98 | 23.8K | 91,819 | — | ↗ |
| 2024-06-13 | POST LEONARD E | Director | S-Sale | D | Ordinary Shares | 2,222 | 5.14 | 11.4K | 15,999 | — | ↗ |
| 2024-06-13 | Meek David D. | Director | S-Sale | D | Ordinary Shares | 2,229 | 5.12 | 11.4K | 20,252 | — | ↗ |
| 2024-06-13 | Kaye Jack | Director | S-Sale | D | Ordinary Shares | 2,218 | 5.16 | 11.4K | 6,501 | — | ↗ |
| 2024-06-13 | Jacques Rachelle Suzanne | Director | S-Sale | D | Ordinary Shares | 2,221 | 5.14 | 11.4K | 14,408 | — | ↗ |
| 2024-06-13 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 3,504 | 5.12 | 17.9K | 44,165 | — | ↗ |
| 2024-06-13 | Balachandran Madhavan | Director | S-Sale | D | Ordinary Shares | 2,231 | 5.12 | 11.4K | 23,759 | — | ↗ |
| 2024-03-01 | Potts Jeannette | Officer | A-Award | A | Ordinary Shares | 49,500 | 0.00 | — | 96,600 | — | ↗ |
| 2024-03-01 | Kapusta Matthew C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 259,500 | 5.59 | 1.45M | 259,500 | — | ↗ |
| 2024-03-01 | KLEMT CHRISTIAN | Officer | A-Award | A | Stock Option (Right to Buy) | 85,500 | 5.59 | 477.9K | 85,500 | — | ↗ |
| 2024-03-01 | CALOZ PIERRE | Officer | A-Award | A | Stock Option (Right to Buy) | 57,000 | 5.59 | 318.6K | 57,000 | — | ↗ |
| 2024-03-01 | Abi-Saab Walid | Officer | A-Award | A | Stock Option (Right to Buy) | 85,500 | 5.59 | 477.9K | 85,500 | — | ↗ |
| 2024-02-26 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 27,904 | 6.35 | 177.2K | 440,839 | — | ↗ |
| 2024-02-26 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 15,906 | 6.38 | 101.5K | 116,948 | — | ↗ |
| 2024-02-26 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 9,455 | 6.47 | 61.2K | 85,643 | — | ↗ |
| 2023-12-31 | Kaye Jack | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-27 | Abi-Saab Walid | Officer | — | D | Stock Option (Right to Buy) | 115,800 | 11.47 | 1.33M | 0 | — | ↗ |
| 2023-09-18 | Dolmetsch Ricardo | Officer | S-Sale | D | Ordinary Shares | 5,841 | 7.46 | 43.6K | 163,404 | — | ↗ |
| 2023-07-10 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 15,117 | 11.36 | 171.7K | 95,098 | — | ↗ |
| 2023-06-16 | Springhorn Jeremy P. | Director | S-Sale | D | Ordinary Shares | 2,286 | 18.88 | 43.2K | 25,987 | — | ↗ |
| 2023-06-16 | Soteropoulos Paula | Director | S-Sale | D | Ordinary Shares | 2,275 | 18.99 | 43.2K | 22,423 | — | ↗ |
| 2023-06-16 | POST LEONARD E | Director | S-Sale | D | Ordinary Shares | 2,291 | 18.83 | 43.1K | 18,221 | — | ↗ |
| 2023-06-16 | Meek David D. | Director | S-Sale | D | Ordinary Shares | 2,290 | 18.85 | 43.2K | 22,481 | — | ↗ |
| 2023-06-16 | Kaye Jack | Director | S-Sale | D | Ordinary Shares | 2,280 | 18.93 | 43.2K | 34,119 | — | ↗ |
| 2023-06-16 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 1,587 | 18.94 | 30.1K | 132,854 | — | ↗ |
| 2023-06-16 | Jacques Rachelle Suzanne | Director | S-Sale | D | Ordinary Shares | 2,301 | 18.76 | 43.2K | 16,629 | — | ↗ |
| 2023-06-16 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 3,228 | 18.88 | 60.9K | 47,669 | — | ↗ |
| 2023-06-16 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 2,920 | 18.80 | 54.9K | 110,215 | — | ↗ |
| 2023-06-16 | Balachandran Madhavan | Director | S-Sale | D | Ordinary Shares | 2,283 | 18.91 | 43.2K | 25,990 | — | ↗ |
| 2023-06-13 | Springhorn Jeremy P. | Director | A-Award | A | Stock Option (Right to Buy) | 17,060 | 20.18 | 344.3K | 17,060 | — | ↗ |
| 2023-06-13 | Soteropoulos Paula | Director | A-Award | A | Stock Option (Right to Buy) | 17,060 | 20.18 | 344.3K | 17,060 | — | ↗ |
| 2023-06-13 | Potts Jeannette | Officer | A-Award | A | Option (Right to Buy) | 81,300 | 20.18 | 1.64M | 81,300 | — | ↗ |
| 2023-06-13 | POST LEONARD E | Director | A-Award | A | Stock Option (Right to Buy) | 17,060 | 20.18 | 344.3K | 17,060 | — | ↗ |
| 2023-06-13 | Meek David D. | Director | A-Award | A | Ordinary Shares | 8,700 | 0.00 | — | 24,771 | — | ↗ |
| 2023-06-13 | Kaye Jack | Director | A-Award | A | Ordinary Shares | 8,700 | 0.00 | — | 36,399 | — | ↗ |
| 2023-06-13 | Jacques Rachelle Suzanne | Director | A-Award | A | Ordinary Shares | 8,700 | 0.00 | — | 18,930 | — | ↗ |
| 2023-06-13 | Gut Robert | Director | A-Award | A | Stock Option (Right to Buy) | 17,060 | 20.18 | 344.3K | 17,060 | — | ↗ |
| 2023-06-13 | Balachandran Madhavan | Director | A-Award | A | Stock Option (Right to Buy) | 17,060 | 20.18 | 344.3K | 17,060 | — | ↗ |
| 2023-03-07 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 585 | 21.36 | 12.5K | 90,381 | — | ↗ |
| 2023-03-07 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 2,521 | 21.39 | 53.9K | 468,743 | — | ↗ |
| 2023-03-07 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 986 | 21.36 | 21.1K | 134,441 | — | ↗ |
| 2023-03-07 | Dolmetsch Ricardo | Officer | S-Sale | D | Ordinary Shares | 837 | 21.04 | 17.6K | 169,245 | — | ↗ |
| 2023-03-07 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 990 | 21.33 | 21.1K | 113,135 | — | ↗ |
| 2023-02-28 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 1,212 | 21.04 | 25.5K | 90,966 | — | ↗ |
| 2023-02-28 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 5,021 | 20.90 | 104.9K | 471,264 | — | ↗ |
| 2023-02-28 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 1,369 | 20.90 | 28.6K | 135,427 | — | ↗ |
| 2023-02-28 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 1,431 | 21.16 | 30.3K | 42,197 | — | ↗ |
| 2023-02-27 | Springhorn Jeremy P. | Director | S-Sale | D | Ordinary Shares | 384 | 20.41 | 7.8K | 19,573 | — | ↗ |
| 2023-02-27 | Soteropoulos Paula | Director | S-Sale | D | Ordinary Shares | 384 | 19.97 | 7.7K | 15,998 | — | ↗ |
| 2023-02-27 | POST LEONARD E | Director | S-Sale | D | Ordinary Shares | 389 | 19.73 | 7.7K | 11,812 | — | ↗ |
| 2023-02-27 | Meek David D. | Director | S-Sale | D | Ordinary Shares | 389 | 19.71 | 7.7K | 16,071 | — | ↗ |
| 2023-02-27 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 5,514 | 19.99 | 110.2K | 92,178 | — | ↗ |
| 2023-02-27 | Kaye Jack | Director | S-Sale | D | Ordinary Shares | 384 | 19.99 | 7.7K | 27,699 | — | ↗ |
| 2023-02-27 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 18,141 | 19.86 | 360.3K | 477,670 | — | ↗ |
| 2023-02-27 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 9,824 | 20.10 | 197.5K | 136,796 | — | ↗ |
| 2023-02-27 | Jacques Rachelle Suzanne | Director | S-Sale | D | Ordinary Shares | 384 | 20.02 | 7.7K | 10,230 | — | ↗ |
| 2023-02-27 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 537 | 19.79 | 10.6K | 43,628 | — | ↗ |
| 2023-02-27 | Dolmetsch Ricardo | Officer | S-Sale | D | Ordinary Shares | 6,944 | 19.58 | 136.0K | 170,082 | — | ↗ |
| 2023-02-27 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 4,284 | 19.59 | 83.9K | 114,206 | — | ↗ |
| 2023-02-27 | Balachandran Madhavan | Director | S-Sale | D | Ordinary Shares | 384 | 19.99 | 7.7K | 19,573 | — | ↗ |
| 2023-02-23 | Kapusta Matthew C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 256,500 | 20.06 | 5.15M | 256,500 | — | ↗ |
| 2023-02-23 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 37,400 | 0.00 | — | 146,620 | — | ↗ |
| 2023-02-23 | Dolmetsch Ricardo | Officer | A-Award | A | Ordinary Shares | 46,700 | 0.00 | — | 177,026 | — | ↗ |
| 2023-02-23 | CALOZ PIERRE | Officer | A-Award | A | Ordinary Shares | 46,700 | 0.00 | — | 118,490 | — | ↗ |
| 2023-02-20 | Kuta Alexander Edward III | Officer | A-Award | A | Ordinary Shares | 2,040 | 0.00 | — | 97,692 | — | ↗ |
| 2023-02-20 | Kapusta Matthew C | Director / Officer | A-Award | A | Ordinary Shares | 5,830 | 0.00 | — | 374,311 | — | ↗ |
| 2023-02-20 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 2,040 | 0.00 | — | 109,220 | — | ↗ |
| 2023-02-20 | Dolmetsch Ricardo | Officer | A-Award | A | Ordinary Shares | 2,920 | 0.00 | — | 130,326 | — | ↗ |
| 2023-02-20 | CALOZ PIERRE | Officer | A-Award | A | Ordinary Shares | 2,920 | 0.00 | — | 71,790 | — | ↗ |
| 2023-01-18 | Soteropoulos Paula | Director | M-Exempt | A | Ordinary Shares | 6,000 | 5.37 | 32.2K | 22,382 | — | ↗ |
| 2022-12-14 | Soteropoulos Paula | Director | M-Exempt | A | Ordinary Shares | 3,800 | 0.00 | — | 20,182 | — | ↗ |
| 2022-12-13 | Soteropoulos Paula | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 0.00 | — | 8,000 | — | ↗ |
| 2022-12-09 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 2,338 | 22.34 | 52.2K | 95,652 | — | ↗ |
| 2022-12-09 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 6,648 | 22.44 | 149.2K | 368,481 | — | ↗ |
| 2022-12-09 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 2,608 | 22.35 | 58.3K | 107,180 | — | ↗ |
| 2022-12-09 | Dolmetsch Ricardo | Officer | S-Sale | D | Ordinary Shares | 2,219 | 22.30 | 49.5K | 127,406 | — | ↗ |
| 2022-12-09 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 2,941 | 22.22 | 65.3K | 68,870 | — | ↗ |
| 2022-11-29 | Soteropoulos Paula | Director | M-Exempt | D | Stock Option (Right to Buy) | 6,200 | 0.00 | — | 3,800 | — | ↗ |
| 2022-11-22 | Kuta Alexander Edward III | Officer | A-Award | A | Ordinary Shares | 5,100 | 0.00 | — | 97,990 | — | ↗ |
| 2022-11-22 | Kapusta Matthew C | Director / Officer | A-Award | A | Ordinary Shares | 14,575 | 0.00 | — | 375,129 | — | ↗ |
| 2022-11-22 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 5,100 | 0.00 | — | 109,788 | — | ↗ |
| 2022-11-22 | Dolmetsch Ricardo | Officer | A-Award | A | Ordinary Shares | 7,300 | 0.00 | — | 129,625 | — | ↗ |
| 2022-11-22 | CALOZ PIERRE | Officer | A-Award | A | Ordinary Shares | 7,300 | 0.00 | — | 71,811 | — | ↗ |
| 2022-09-21 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 2,306 | 18.65 | 43.0K | 92,890 | — | ↗ |
| 2022-07-28 | Kuta Alexander Edward III | Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,358 | 5.31 | 145.3K | 0 | — | ↗ |
| 2022-07-27 | Kuta Alexander Edward III | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,404 | 5.31 | 55.2K | 27,358 | — | ↗ |
| 2022-07-22 | Kuta Alexander Edward III | Officer | M-Exempt | A | Ordinary Shares | 5,643 | 5.31 | 30.0K | 100,839 | — | ↗ |
| 2022-07-21 | Kuta Alexander Edward III | Officer | M-Exempt | A | Ordinary Shares | 595 | 5.31 | 3.2K | 95,791 | — | ↗ |
| 2022-06-16 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 1,687 | 13.20 | 22.3K | 104,688 | — | ↗ |
| 2022-06-16 | CALOZ PIERRE | Officer | S-Sale | D | Ordinary Shares | 7,575 | 13.21 | 100.1K | 64,511 | — | ↗ |
| 2022-06-15 | Springhorn Jeremy P. | Director | A-Award | A | Ordinary Shares | 9,080 | 0.00 | — | 19,957 | — | ↗ |
| 2022-06-15 | Soteropoulos Paula | Director | A-Award | A | Stock Option (Right to Buy) | 17,810 | 14.08 | 250.8K | 17,810 | — | ↗ |
| 2022-06-15 | POST LEONARD E | Director | A-Award | A | Stock Option (Right to Buy) | 17,810 | 0.00 | — | 17,810 | — | ↗ |
| 2022-06-15 | Meek David D. | Director | A-Award | A | Ordinary Shares | 9,080 | 0.00 | — | 16,460 | — | ↗ |
| 2022-06-15 | Kaye Jack | Director | A-Award | A | Ordinary Shares | 9,080 | 0.00 | — | 28,083 | — | ↗ |
| 2022-06-15 | Jacques Rachelle Suzanne | Director | A-Award | A | Ordinary Shares | 9,080 | 0.00 | — | 10,614 | — | ↗ |
| 2022-06-15 | Gut Robert | Director | A-Award | A | Stock Option (Right to Buy) | 17,810 | 0.00 | — | 17,810 | — | ↗ |
| 2022-06-15 | Balachandran Madhavan | Director | A-Award | A | Ordinary Shares | 9,080 | 0.00 | — | 19,957 | — | ↗ |
| 2022-02-28 | Springhorn Jeremy P. | Director | S-Sale | D | Ordinary Shares | 602 | 16.70 | 10.1K | 10,877 | — | ↗ |
| 2022-02-28 | Soteropoulos Paula | Director | S-Sale | D | Ordinary Shares | 596 | 16.87 | 10.1K | 7,302 | — | ↗ |
| 2022-02-28 | POST LEONARD E | Director | S-Sale | D | Ordinary Shares | 795 | 16.64 | 13.2K | 3,121 | — | ↗ |
| 2022-02-28 | Meek David D. | Director | S-Sale | D | Ordinary Shares | 602 | 16.70 | 10.1K | 7,380 | — | ↗ |
| 2022-02-28 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 3,405 | 16.72 | 56.9K | 95,156 | — | ↗ |
| 2022-02-28 | Kaye Jack | Director | S-Sale | D | Ordinary Shares | 600 | 16.76 | 10.1K | 19,003 | — | ↗ |
| 2022-02-28 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 10,195 | 16.70 | 170.3K | 360,554 | — | ↗ |
| 2022-02-28 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 4,075 | 16.80 | 68.5K | 106,375 | — | ↗ |
| 2022-02-28 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 1,602 | 16.70 | 26.8K | 35,085 | — | ↗ |
| 2022-02-28 | Dolmetsch Ricardo | Officer | S-Sale | D | Ordinary Shares | 1,484 | 16.68 | 24.8K | 122,325 | — | ↗ |
| 2022-02-28 | Balachandran Madhavan | Director | S-Sale | D | Ordinary Shares | 602 | 16.70 | 10.1K | 10,877 | — | ↗ |
| 2022-02-24 | Springhorn Jeremy P. | Director | A-Award | A | Ordinary Shares | 1,534 | 0.00 | — | 11,479 | — | ↗ |
| 2022-02-24 | Soteropoulos Paula | Director | A-Award | A | Stock Option (Right to Buy) | 2,645 | 16.04 | 42.4K | 2,645 | — | ↗ |
| 2022-02-24 | POST LEONARD E | Director | A-Award | A | Stock Option (Right to Buy) | 2,645 | 16.04 | 42.4K | 2,645 | — | ↗ |
| 2022-02-24 | Meek David D. | Director | A-Award | A | Stock Option (Right to Buy) | 2,645 | 16.04 | 42.4K | 2,645 | — | ↗ |
| 2022-02-24 | Kuta Alexander Edward III | Officer | A-Award | A | Ordinary Shares | 34,904 | 0.00 | — | 98,601 | — | ↗ |
| 2022-02-24 | Kaye Jack | Director | A-Award | A | Stock Option (Right to Buy) | 2,645 | 16.04 | 42.4K | 2,645 | — | ↗ |
| 2022-02-24 | Kapusta Matthew C | Director / Officer | A-Award | A | Ordinary Shares | 125,073 | 0.00 | — | 370,749 | — | ↗ |
| 2022-02-24 | KLEMT CHRISTIAN | Officer | A-Award | A | Ordinary Shares | 43,630 | 0.00 | — | 110,450 | — | ↗ |
| 2022-02-24 | Jacques Rachelle Suzanne | Director | A-Award | A | Ordinary Shares | 1,534 | 0.00 | — | 1,534 | — | ↗ |
| 2022-02-24 | Gut Robert | Director | A-Award | A | Stock Option (Right to Buy) | 2,645 | 16.04 | 42.4K | 2,645 | — | ↗ |
| 2022-02-24 | Dolmetsch Ricardo | Officer | A-Award | A | Stock Option (Right to Buy) | 94,281 | 16.04 | 1.51M | 94,281 | — | ↗ |
| 2022-02-24 | CALOZ PIERRE | Officer | A-Award | A | Ordinary Shares | 37,086 | 0.00 | — | 72,086 | — | ↗ |
| 2022-02-24 | Balachandran Madhavan | Director | A-Award | A | Stock Option (Right to Buy) | 2,645 | 16.04 | 42.4K | 2,645 | — | ↗ |
| 2022-01-26 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 2,945 | 18.02 | 53.1K | 63,697 | — | ↗ |
| 2022-01-26 | Kapusta Matthew C | Director / Officer | S-Sale | D | Ordinary Shares | 10,901 | 18.10 | 197.3K | 245,676 | — | ↗ |
| 2022-01-26 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 3,963 | 18.03 | 71.5K | 66,820 | — | ↗ |
| 2022-01-26 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 2,348 | 18.12 | 42.5K | 35,153 | — | ↗ |
| 2021-12-15 | Kuta Alexander Edward III | Officer | M-Exempt | A | Ordinary Shares | 6,000 | 5.31 | 31.9K | 72,642 | — | ↗ |
| 2021-11-15 | Kuta Alexander Edward III | Officer | M-Exempt | A | Ordinary Shares | 6,000 | 5.31 | 31.9K | 72,642 | — | ↗ |
| 2021-10-21 | Jacques Rachelle Suzanne | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 28.24 | 282.4K | 10,000 | — | ↗ |
| 2021-10-15 | Kuta Alexander Edward III | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,000 | 5.31 | 31.9K | 56,000 | — | ↗ |
| 2021-09-21 | Kuta Alexander Edward III | Officer | S-Sale | D | Ordinary Shares | 2,229 | 36.71 | 81.8K | 66,642 | — | ↗ |
| 2021-09-21 | KLEMT CHRISTIAN | Officer | S-Sale | D | Ordinary Shares | 2,400 | 38.00 | 91.2K | 70,783 | — | ↗ |
| 2021-09-21 | Gut Robert | Director | S-Sale | D | Ordinary Shares | 4,500 | 36.61 | 164.7K | 37,501 | — | ↗ |
| 2021-09-16 | Dolmetsch Ricardo | Officer | S-Sale | D | Ordinary Shares | 8,603 | 37.10 | 319.2K | 69,126 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.9K
Shares Outstanding
61.60M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Matthew Kapusta Chief Executive Officer | 676.2K | — | 1.08M | 1.16M | 345.1K | 1.5K | 3.29M | 67.99% | ↗ |
| 2 | 2025 | Christian Klemt Chief Financial Officer | 539.2K | — | 795.7K | 851.8K | 197.8K | 23.0K | 2.41M | 68.43% | ↗ |
| 3 | 2025 | Walid Abi-Saab Chief Medical Officer | 583.8K | — | 414.2K | 446.2K | 258.3K | 103.2K | 1.81M | 47.65% | ↗ |
| 4 | 2025 | Jeannette Potts Chief Legal and Compliance Officer | 495.0K | — | 381.5K | 405.6K | 178.3K | 9.9K | 1.50M | 52.48% | ↗ |
| 5 | 2024 | Matthew Kapusta Chief Executive Officer | 656.6K | — | 1.11M | 840.8K | 433.6K | 1.5K | 3.08M | 63.33% | ↗ |
| 6 | 2024 | Pierre Caloz Chief Operations Officer | 524.0K | — | 223.6K | 184.7K | — | 1.04M | 1.98M | 20.67% | ↗ |
| 7 | 2024 | Walid Abi-Saab Chief Medical Officer | 541.4K | — | 276.7K | 277.0K | 311.3K | 93.5K | 1.50M | 36.92% | ↗ |
| 8 | 2024 | Christian Klemt Chief Financial Officer | 449.2K | — | 370.7K | 277.0K | 206.6K | 23.9K | 1.33M | 48.79% | ↗ |
| 9 | 2024 | Jeannette Potts Chief Legal and Compliance Officer | 480.7K | — | 276.7K | 277.0K | 211.6K | 9.9K | 1.29M | 42.85% | ↗ |
| 10 | 2023 | Matthew Kapusta Chief Executive Officer | 635.1K | — | 2.50M | 3.06M | 342.9K | 4.3K | 6.58M | 84.55% | ↗ |
| 11 | 2023 | Ricardo Dolmetsch Former Chief Scientific Officer | 509.2K | — | 962.0K | 963.0K | — | 1.03M | 3.49M | 55.19% | ↗ |
| 12 | 2023 | Pierre Caloz Chief Operations Officer | 554.1K | — | 962.0K | 963.0K | 246.9K | 81.6K | 2.81M | 68.56% | ↗ |
| 13 | 2023 | Richard Porter Chief Business and Scientific Officer | 488.0K | — | 1.03M | 856.9K | 173.0K | 71.1K | 2.62M | 72.05% | ↗ |
| 14 | 2023 | Jeannette Potts Chief Legal and Compliance Officer | 277.2K | — | 950.5K | 951.6K | 102.1K | 7.0K | 2.31M | 82.31% | ↗ |
| 15 | 2023 | Christian Klemt Chief Financial Officer | 407.1K | — | 770.4K | 770.6K | 146.0K | 22.3K | 2.12M | 72.81% | ↗ |
| 16 | 2022 | Matthew Kapusta Chief Executive Officer | 609.5K | — | 2.46M | 2.01M | 512.4K | 9.2K | 5.63M | 79.43% | ↗ |
| 17 | 2022 | Ricardo Dolmetsch Former Chief Scientific Officer | 524.6K | — | 1.11M | 877.1K | 350.4K | 9.2K | 2.89M | 68.53% | ↗ |
| 18 | 2022 | Ricardo Dolmetsch President, Research & Development | 524.6K | — | 1.11M | 877.1K | 350.4K | 9.2K | 2.89M | 68.53% | ↗ |
| 19 | 2022 | Pierre Caloz Chief Operations Officer | 501.2K | — | 824.2K | 594.9K | 344.1K | 105.8K | 2.37M | 59.87% | ↗ |
| 20 | 2022 | Christian Klemt Chief Financial Officer | 358.3K | — | 860.1K | 699.8K | 191.4K | 16.7K | 2.13M | 73.36% | ↗ |
| 21 | 2022 | Alexander Kuta Executive Vice President, Operations | 459.7K | — | 720.1K | 559.9K | 248.4K | 9.2K | 2.02M | 63.44% | ↗ |
| 22 | 2021 | Matthew Kapusta Chief Executive Officer | 583.5K | — | 2.07M | 2.07M | 350.1K | 8.7K | 5.10M | 80.98% | ↗ |
| 23 | 2021 | Pierre Caloz Chief Operations Officer | 317.0K | — | 1.21M | 1.50M | 161.7K | 43.9K | 3.23M | 83.81% | ↗ |
| 24 | 2021 | Christian Klemt Chief Financial Officer | 344.6K | — | 934.5K | 928.9K | 142.0K | 18.4K | 2.37M | 78.68% | ↗ |
| 25 | 2021 | Alexander Kuta Executive Vice President, Operations | 444.8K | — | 692.6K | 692.6K | 174.4K | 8.7K | 2.03M | 68.09% | ↗ |
| 26 | 2021 | Ricardo Dolmetsch Former Chief Scientific Officer | 506.0K | — | 471.0K | 471.0K | 253.0K | 8.7K | 1.74M | 54.22% | ↗ |
| 27 | 2021 | Ricardo Dolmetsch President, Research & Development | 506.0K | — | 471.0K | 471.0K | 253.0K | 8.7K | 1.74M | 54.22% | ↗ |
| 28 | 2020 | Matthew Kapusta Chief Executive Officer | 584.5K | — | 1.75M | 1.75M | 348.4K | 7.8K | 4.47M | 78.38% | ↗ |
| 29 | 2020 | Ricardo Dolmetsch President, Research & Development | 144.2K | — | 2.51M | 724.6K | 75.5K | 49.8K | 3.51M | 92.15% | ↗ |
| 30 | 2020 | Alexander Kuta Executive Vice President, Operations | 452.6K | — | 641.4K | 640.9K | 172.7K | 8.6K | 1.93M | 66.27% | ↗ |
| 31 | 2020 | Christian Klemt Chief Financial Officer | 274.3K | — | 427.6K | 427.3K | 100.8K | 17.5K | 1.25M | 68.53% | ↗ |
| 32 | 2017 | Matthew Kapusta, Chief Executive Officer and Principal Financial Officer | 468.1K | 257.6K | 2.61M | 560.5K | — | 31.1K | 3.93M | 80.74% | ↗ |
| 33 | 2017 | Harald Petry, Chief Scientific Officer | 199.8K | — | 1.18M | 79.3K | — | 486.3K | 1.94M | 64.70% | ↗ |
| 34 | 2017 | Paul Firuta, Chief Commercial Officer | 350.0K | 140.3K | 613.7K | 270.3K | — | 33.2K | 1.41M | 62.81% | ↗ |
| 35 | 2017 | Jonathan Garen, Chief Business Officer | 348.5K | 139.7K | 613.7K | 87.5K | — | 30.0K | 1.22M | 57.50% | ↗ |
| 36 | 2016 | Charles Richard, SVP, Research and Development Neuroscience | 352.6K | 103.8K | 69.1K | 789.0K | — | 364.1K | 1.68M | 51.12% | ↗ |
| 37 | 2016 | Matthew Kapusta, Chief Executive Officer and interim Chief Financial Officer | 380.0K | 142.3K | 111.1K | 574.9K | — | 29.2K | 1.24M | 55.43% | ↗ |
| 38 | 2016 | Matthew Kapusta, Chief Executive Officer and Principal Financial Officer | 380.0K | 142.3K | 111.1K | 574.9K | — | 29.2K | 1.24M | 55.43% | ↗ |
| 39 | 2016 | Deya Corzo, SVP, Therapeutic area head Liver/Metabolism | 353.1K | 123.6K | 129.6K | 90.9K | — | 375.1K | 1.07M | 20.56% | ↗ |
| 40 | 2016 | Harald Petry, Chief Scientific Officer | 262.3K | 76.9K | 29.8K | 88.4K | — | 46.3K | 503.7K | 23.47% | ↗ |
| 41 | 2016 | Paul Firuta, Chief Commercial Officer | 213.3K | 73.7K | 15.9K | 158.3K | — | 24.0K | 485.3K | 35.91% | ↗ |
| 42 | 2016 | Jonathan Garen, Chief Business Officer | 155.8K | 57.8K | 15.9K | 27.2K | — | 18.1K | 274.8K | 15.70% | ↗ |
| 43 | 2016 | Daniel Soland, Chief Executive Officer | 376.7K | — | — | — | — | 28.3K | 250.5K | 0.00% | ↗ |
| 44 | 2015 | Matthew Kapusta, Chief Executive Officer and interim Chief Financial Officer | 350.0K | 140.0K | — | 331.3K | — | 175.0K | 996.3K | 33.25% | ↗ |
| 45 | 2015 | Deya Corzo, SVP, Therapeutic area head Liver/Metabolism | 346.0K | 120.0K | — | 199.8K | — | 22.0K | 687.8K | 29.05% | ↗ |
| 46 | 2015 | Charles Richard, SVP, Research and Development Neuroscience | 196.8K | 53.5K | — | 394.5K | — | 11.0K | 655.9K | 60.15% | ↗ |
| 47 | 2015 | Daniel Soland, Chief Executive Officer | — | — | — | 154.5K | — | — | 154.5K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director | 1M | male |
| Walid Abi-Saab | Chief Medical Officer | 945.3K | — |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | 760.0K | male |
| Richard Porter | Chief Business & Scientific Officer | 732.2K | male |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary | 712.8K | — |
| Amin Abujoub | Chief Technical Operations Officer | — | — |
| Kylie O'Keefe | Chief Customer & Strategy Officer | — | female |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | — | — |
| Erin Boyer | Chief People & Culture Officer | — | female |
| Tamara Tugal | Business Development Director | — | — |
| Chiara Elizabeth Russo | Senior Director of Investor Relations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for QURE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
